{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=74&state=Alabama",
    "query": {
      "state": "Alabama",
      "city": "Birmingham",
      "page": 74
    },
    "page_size": 10
  },
  "pagination": {
    "page": 74,
    "page_size": 10,
    "total_count": 9532,
    "total_pages": 954,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=75&state=Alabama&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=73&state=Alabama&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T13:40:56.412Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00303498",
      "title": "A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diastolic Heart Failure"
      ],
      "interventions": [
        {
          "name": "Sitexsentin sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2006-03-27",
      "completion_date": "2008-05-01",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-10-28T13:40:56.412Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00303498"
    },
    {
      "nct_id": "NCT03165734",
      "title": "A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Pacritinib",
          "type": "DRUG"
        },
        {
          "name": "Physician's Choice medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 407,
      "start_date": "2017-06-26",
      "completion_date": "2028-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-28T13:40:56.412Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03165734"
    },
    {
      "nct_id": "NCT00317434",
      "title": "Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "19 Years to 90 Years · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2005-11",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2009-12-15",
      "last_synced_at": "2026-10-28T13:40:56.412Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Indianapolis, Indiana",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00317434"
    },
    {
      "nct_id": "NCT02677298",
      "title": "Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Frown Lines"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Croma-Pharma GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 784,
      "start_date": "2016-03-02",
      "completion_date": "2017-11-16",
      "has_results": true,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-10-28T13:40:56.412Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Encino, California • San Francisco, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02677298"
    },
    {
      "nct_id": "NCT03776071",
      "title": "A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Enzastaurin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Denovo Biopharma LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2020-12-16",
      "completion_date": "2024-02-29",
      "has_results": false,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-10-28T13:40:56.412Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03776071"
    },
    {
      "nct_id": "NCT00005009",
      "title": "Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "Varivax®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 7,
      "start_date": "1998-02",
      "completion_date": "2001-06-16",
      "has_results": false,
      "last_update_posted_date": "2017-02-16",
      "last_synced_at": "2026-10-28T13:40:56.412Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005009"
    },
    {
      "nct_id": "NCT00264732",
      "title": "A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Uterine Cervical Dysplasia"
      ],
      "interventions": [
        {
          "name": "Amolimogene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 25 Years · Female only"
      },
      "enrollment_count": 251,
      "start_date": "2005-07",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2013-05-29",
      "last_synced_at": "2026-10-28T13:40:56.412Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00264732"
    },
    {
      "nct_id": "NCT04905693",
      "title": "Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis",
        "Interstitial Lung Disease",
        "Progressive Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Inhaled Treprostinil",
          "type": "DRUG"
        },
        {
          "name": "Treprostinil Ultrasonic Nebulizer",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1850,
      "start_date": "2022-09-06",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-28T13:40:56.412Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Franklin",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04905693"
    },
    {
      "nct_id": "NCT00274521",
      "title": "Tiotropium (Spiriva) Rehabilitation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2001-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-11-01",
      "last_synced_at": "2026-10-28T13:40:56.412Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Deer Park, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Deer Park",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274521"
    },
    {
      "nct_id": "NCT01703533",
      "title": "A Safety Study of NNZ-2566 in Patients With Rett Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rett Syndrome"
      ],
      "interventions": [
        {
          "name": "NNZ-2566",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neuren Pharmaceuticals Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 45 Years · Female only"
      },
      "enrollment_count": 67,
      "start_date": "2013-03",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2018-02-05",
      "last_synced_at": "2026-10-28T13:40:56.412Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Saint Paul, Minnesota • Houston, Texas",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01703533"
    }
  ]
}